Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.

摘要: Background: Metastatic pancreatic carcinoma is an incurable disease and gemcitabine remains the standard of care in first-line chemotherapy. Recently, fluorouracil/ leucovorin combined with irinotecan oxaliplatin (FOLFIRINOX) demonstrated their superiority therapy. The objective this study was to determine efficacy FOLFIRINOX either first- second-line treatment compare its regard location primary tumor. Patients Methods: We performed a retrospective analysis clinical factors associated patients' survival using cohort 42 patients treated by or (2006-2011) control matched on sex age without obtained from previous period time (2001-2005). Results: median follow-up 10 months. overall months for whole 12 at second-line, respectively (p<0.05). In multivariate model, among classical prognosis factors, only head poor outcome. 8 14 corpse tail (p=0.02). cohort, Using performance status 9 versus 6.5 tumor, tumor Conclusion: This suggests same used second- line therapy cancer. Importantly, compared favorably tail. Further prospective trials are warranted evaluate pancreas.